APHIN exists to create awareness, prevent and treat hepatitis virus in Nigeria and other developing countries.
The objectives for which the Organisation is established are:
1. To provide enlightenment about Hepatitis virus, the mode of transmission of the disease, its effect, prevention and treatment through awareness campaign, organizing of seminars, media presentation and conferences.
2. To establish pre-and post counseling offices with the aim of providing proficient physical and emotional healing.
3. To create empowerment centers in all the states of the federation and also in other developing countries to help in spreading the knowledge of hepatitis and hence curb the rapidly increasing cases of hepatitis
4. To receive grants; contributions, donations and money from individual, organizations, Business companies, Foundations, charitable organizations, missions, churches, ministries, mosques, NGOs, government, and International institutions on behalf of individuals incapable of paying for their treatments and getting it to them
5. To conduct researches on the prevalence of Hepatitis virus as well as screening, treatment and vaccination
6. To organize talk shows, concerts, seminars and conferences in schools, communities, towns, villages, market places, Hotels, churches, mosques and such related places to sensitize the people and to prevent hepatitis
7. To affiliate with other NGOs, Government agencies, media houses and individuals when necessary in order to create awareness on hepatitis
8. To carryout such activities that will educate and protect the society from the scourge of hepatitis
9. To organize programmes, jingles, Advertisements on TV, Radio, and other means of publicity such as billboards, pamphlets and poster
10. To conduct research, create awareness and enlightenment on other related rampaging infections in the country as the need arises
Hepatitis and PWID/harm reduction
11:35 – 11:40
Chair: WHO – Intro and set the scene.
11:40 – 11:55
Co-chair: EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe.
11:55 – 12:00
ID 29: Ema Pos (not yet registered)
Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation.
12:05 – 12:10
ID 152: Brian Conway (Registered in person)
Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.
12:10 – 12:15
ID 212: Jasmine West (not yet registered)
Title: From lived experience to lived expertise: a syndemic approach.
12:15 – 12:20
ID: 299 Mercy Nyakowa (Registered in person)
Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya
12:20 – 12:25
ID: 133 Nalinikanta Rajkumar (Registered in person)
Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?
12:25 – 12:30
Q&A and closing remarks
tHIS
IS
BEN’S
BIG
TEST
effective case finding strategies
Supported by Vir Biotechnology, Inc
During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.
Session Agenda
14:40 – 14:45
Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)
14:45 – 15:05
Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology
15:05 – 15:10
Final remarks and close
